

Special Issue

Effects of Natural Products to Manage Metabolic Syndrome-Associated Pathologies

Message from the Guest Editors

Metabolic syndrome involves obesity, insulin resistance, dyslipidemia, hypertension, and chronic inflammation, leading to diseases like type 2 diabetes, cardiovascular issues, and liver disorders. Natural products have gained attention for their bioactive compounds and multi-target effects. This Special Issue focuses on recent progress in natural products—such as plant extracts, phytochemicals, nutraceuticals, functional foods, marine compounds, probiotics, and microbial metabolites—for managing metabolic syndrome. We invite original research, reviews, and mechanistic studies on bioactivity, molecular action, pharmacology, and clinical potential. Topics of interest include antioxidant, anti-inflammatory, antidiabetic, anti-obesity, cardioprotective, and microbiome-modulating properties. This Special Issue seeks to provide an interdisciplinary platform to advance knowledge on innovative natural strategies for preventing and treating metabolic syndrome-related diseases.

Guest Editors

Dr. Laura Isabel Arellano-García

1. Nutrition and Obesity Group, Department of Nutrition and Food Science, Faculty of Pharmacy and Lucio Lascaray Research Centre, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain
2. CIBERObn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain
3. BIOARABA Health Research Institute, 01006 Vitoria-Gasteiz, Spain

Dr. Itziar Eseberri

1. Nutrition and Obesity Group, Department of Nutrition and Food Science, Faculty of Pharmacy and Lucio Lascaray Research Centre, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain
2. CIBERObn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain
3. BIOARABA Health Research Institute, 01006 Vitoria-Gasteiz, Spain

Deadline for manuscript submissions

25 February 2027



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 5.7
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/286068

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 5.7
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)